Stanford Cancer Immune Monitoring and Analysis Center (CIMAC)

摘要 对于此次CIMAC更新，斯坦福癌症免疫监测和分析中心 (CIMAC)将继续与NCI和CIMAC/CIDC网络合作，以确定和， 在适当的情况下，领导测试新的免疫治疗方案的试验的相关研究。我们 将参与工作组电话会议、网络会议以及与临床团队的协调。 斯坦福CIMAC进行了高度全面的免疫表型和 NCI确定的临床试验的功能。这些将包括已验证和协调的 第1级分析、经过验证的第2级分析和新提出的探索性第3级分析。对于第1层 在检测方面，我们提出了CyTOF、Singleplex IHC、Olink、TCRseq和RNAseq。对于第2级，我们 提出单细胞TCRseq、MIBI、ATACseq和CyTOF蛋白质组学。对于Tier 3，我们建议 单细胞多糖成像(通过MALDI-ToF)、空间转录(NanoStringDSP平台)、 和单细胞基因组学/蛋白质组学(Space Bio Tapestri和BD Rhapsody平台)。我们会 使用纵向参考材料来跟踪批次间和项目间的一致性。我们 在将数据上传到癌症免疫组织之前，将评估所有检测的质量控制措施 数据共享(CIDC)根据其规范。 我们还将对与以下方面有关的所有化验结果进行生物统计分析 临床结果数据。对于斯坦福大学是CIMAC牵头的那些试验，我们将执行 使用适当的机器学习技术和 多元回归算法，如套索或弹性网络。我们将与 临床团队获取标准化的临床数据，并在 符合NCI指南。

Abstract For this CIMAC renewal, the Stanford Cancer Immune Monitoring and Analysis Center (CIMAC) will continue to collaborate with NCI and the CIMAC/CIDC network to identify and, where appropriate, lead correlative studies for trials testing novel immunotherapy regimens. We will participate in working group calls, network meetings, and coordination with clinical teams. The Stanford CIMAC performs highly comprehensive assays of immune phenotype and function for NCI-identified clinical trials. These will include already validated and harmonized Tier 1 assays, validated Tier 2 assays, and newly proposed exploratory Tier 3 assays. For Tier 1 assays, we propose CyTOF, singleplex IHC, Olink, TCRseq and RNAseq. For Tier 2, we propose single-cell TCRseq, MIBI, ATACseq, and CyTOF proteomics. For Tier 3, we propose single-cell glycan imaging (by MALDI-ToF), spatial transcriptomics (Nanostring DSP platform), and single-cell genomics/proteomics (Mission Bio Tapestri and BD Rhapsody platforms). We will use longitudinal reference materials for tracking inter-batch and inter-project consistency. We will assess quality control measures on all assays before uploading data to the Cancer Immune Data Commons (CIDC) according to their specifications. We will also perform biostatistical analysis of results for all assays performed, in relation to clinical outcome data. For those trials where Stanford is the lead CIMAC, we will perform integrative analysis across assays, using appropriate machine learning techniques and multivariate regression algorithms such as LASSO or Elastic Net. We will work closely with the clinical teams to obtain standardized clinical data, and to disseminate and publish results in accordance with NCI guidelines.